Top

11-05-2024 | Pancreatic Cancer | Review

Expanding access to genetic testing for pancreatic cancer

Authors: Nicolette Juliana Rodriguez, Sapna Syngal

Abstract

Among individuals with pancreatic ductal adenocarcinoma (PDAC) 5–10% have a pathogenic germline variant (PGV) in a PDAC susceptibility gene. Guidelines recommend genetic testing among all individuals with PDAC. Additionally, at-risk relatives of PDAC patients benefit from their own genetic education, risk assessment, and testing. Multigene panel testing (MGPT) can identify individuals with inherited cancer risk who can benefit from early cancer surveillance and risk reduction strategies. This manuscript discusses various healthcare delivery models for MGPT including traditional in-person genetic counseling, novel integrated in-person infrastructures, telemedicine genetics care via telephone- or video-visits and direct-to-consumer testing. Barriers and facilitators to care on the individual, provider, and system level are also outlined including specific considerations for historically marginalized communities.

Siegel RL, Miller KD, Wagle NS, Jemal A, Cancer statistics (2023) CA Cancer J Clin. Jan 2023;73(1):17–48. https://doi.org/10.3322/caac.21763

American Cancer Society. Cancer Facts & Fig. (2024) Atlanta: American Cancer Society; 2024

Hu C, Hart SN, Polley EC et al (2018) Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA. 06 19. ;319(23):2401–2409. https://doi.org/10.1001/jama.2018.6228

Shindo K, Yu J, Suenaga M et al (2017) Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol Oct 20(30):3382–3390. https://doi.org/10.1200/JCO.2017.72.3502CrossRef

Brand R, Borazanci E, Speare V et al (2018) Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer Sep 01(17):3520–3527. https://doi.org/10.1002/cncr.31628CrossRef

Grant RC, Selander I, Connor AA et al (2015) Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterol Mar 148(3):556–564. https://doi.org/10.1053/j.gastro.2014.11.042CrossRef

Yurgelun MB, Chittenden AB, Morales-Oyarvide V et al (2019) Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med 01(1):213–223. https://doi.org/10.1038/s41436-018-0009-5CrossRef

Golan T, Casolino R, Biankin AV et al (2023) Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Ther Adv Med Oncol 15:17588359231189127. https://doi.org/10.1177/17588359231189127CrossRefPubMedPubMedCentral

National Comprehensive Cancer Network (NCCN) (2023) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 3.2023

10.

Walker EJ, Carnevale J, Pedley C et al (2019) Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer 04(2):241–251. https://doi.org/10.1007/s10689-018-0106-2CrossRef

11.

Chittenden A, Haraldsdottir S, Ukaegbu C et al (2021) Implementing systematic genetic counseling and Multigene Germline Testing for individuals with pancreatic Cancer. JCO Oncol Pract 17(2):e236–e247. https://doi.org/10.1200/OP.20.00678CrossRefPubMedPubMedCentral

12.

Kurian AW, Abrahamse P, Furgal A et al (2023) Germline genetic testing after Cancer diagnosis. JAMA Jul 03(1):43–51. https://doi.org/10.1001/jama.2023.9526CrossRef

13.

Stoffel EM, Carethers JM (2020) Current approaches to germline cancer genetic testing. Annu Rev Med 71:85–102. https://doi.org/10.1146/annurev-med-052318-101009CrossRefPubMed

14.

Dbouk M, Katona BW, Brand RE et al (2022) The Multicenter Cancer of pancreas Screening Study: Impact on Stage and Survival. J Clin Oncol Jun 15:JCO2200298. https://doi.org/10.1200/JCO.22.00298CrossRef

15.

Klatte DCF, Boekestijn B, Wasser MNJM et al (2022) Pancreatic Cancer surveillance in carriers of a germline. J Clin Oncol Oct 01(28):3267–3277. https://doi.org/10.1200/JCO.22.00194

16.

Walker EJ, Goldberg D, Gordon KM et al (2021) Implementation of an embedded In-Clinic Genetic Testing Station to optimize germline testing for patients with pancreatic adenocarcinoma. Oncologist Sep 10. https://doi.org/10.1002/onco.13968

17.

Drogan CM, Kindler HL, Gao G, Kupfer SS (2023) Outcomes of Universal Point-of-care genetic testing in diverse patients with pancreatic ductal adenocarcinoma. JCO Precis Oncol Jan 7:e2200196. https://doi.org/10.1200/PO.22.00196CrossRef

18.

Rodriguez NJ, Ricker C, Stoffel EM, Syngal S (2023) Barriers and facilitators to Genetic Education, Risk Assessment, and testing: considerations on advancing Equitable Genetics Care. Gastroenterol Jan 164(1):5–8. https://doi.org/10.1053/j.gastro.2022.11.021CrossRef

19.

Rana HQ, Cochrane SR, Hiller E et al (2018) A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings. J Community Genet Jul 9(3):233–241. https://doi.org/10.1007/s12687-017-0347-zCrossRef

20.

Chou AF, Duncan AR, Hallford G, Kelley DM, Dean LW (2021) Barriers and strategies to integrate medical genetics and primary care in underserved populations: a scoping review. J Community Genet Jul 12(3):291–309. https://doi.org/10.1007/s12687-021-00508-5CrossRef

21.

Srinivasan S, Won NY, Dotson WD, Wright ST, Roberts MC (2020) Barriers and facilitators for cascade testing in genetic conditions: a systematic review. Eur J Hum Genet 12(12):1631–1644. https://doi.org/10.1038/s41431-020-00725-5CrossRef

22.

Rodriguez NJ, Coffin TB, Ward AJ et al (2023) The Racial/ethnic equity in GENetic Education, Risk Assessment, and TEsting (REGENERATE) among black and Latino/a/x communities At-risk for pancreatic Cancer - Preliminary findings from Online Focus Groups. Gastroenterol - DDW 2023 Abstracts 164(6):S–733. https://doi.org/10.1016/S0016-5085(23)02702-6CrossRef

23.

Canedo JR, Wilkins CH, Senft N, Romero A, Bonnet K, Schlundt D (2020) Barriers and facilitators to dissemination and adoption of precision medicine among Hispanics/Latinos. BMC Public Health May 20(1):603. https://doi.org/10.1186/s12889-020-08718-1CrossRef

24.

Hann KEJ, Freeman M, Fraser L et al (2017) Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review. BMC Public Health 05(1):503. https://doi.org/10.1186/s12889-017-4375-8CrossRef

25.

Rosas LG, Nasrallah C, Park VT et al (2020) Perspectives on Precision Health among Racial/Ethnic Minority Communities and the Physicians that serve them. Ethn Dis 30(Suppl 1):137–148. https://doi.org/10.18865/ed.30.S1.137CrossRefPubMedPubMedCentral

26.

Dharwadkar P, Greenan G, Stoffel EM et al (2022) Racial and ethnic disparities in Germline genetic testing of patients with Young-Onset Colorectal Cancer. Clin Gastroenterol Hepatol 02(2):353–361e3. https://doi.org/10.1016/j.cgh.2020.12.025CrossRef

27.

Jagsi R, Griffith KA, Kurian AW et al (2015) Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. J Clin Oncol May 10(14):1584–1591. https://doi.org/10.1200/JCO.2014.58.5885CrossRef

28.

Halder R, Veeravelli S, Cheng C, Estrada-Mendizabal RJ, Recio-Boiles A (2023) Health disparities in Presentation, Treatment, genomic testing, and outcomes of pancreatic Cancer in hispanic and non-hispanic patients. J Racial Ethn Health Disparities Apr 18. https://doi.org/10.1007/s40615-022-01486-1

29.

Triebold M, Skov K, Erickson L et al (2021) Geographical analysis of the distribution of certified genetic counselors in the United States. J Genet Couns 04(2):448–456. https://doi.org/10.1002/jgc4.1331CrossRef

30.

Ayala-Lopez N, Nichols JH (2020) Benefits and risks of direct-to-consumer testing. Arch Pathol Lab Med 10(10):1193–1198. https://doi.org/10.5858/arpa.2020-0078-RACrossRef

31.

Riley BD, Culver JO, Skrzynia C et al (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns Apr 21(2):151–161. https://doi.org/10.1007/s10897-011-9462-xCrossRef

32.

Gorrie A, Gold J, Cameron C, Krause M, Kincaid H (2021) Benefits and limitations of telegenetics: a literature review. J Genet Couns Aug 30(4):924–937. https://doi.org/10.1002/jgc4.1418CrossRef

33.

Rodriguez NJ, Furniss CS, Yurgelun MB et al (2024) A Randomized Trial of two Remote Healthcare Delivery models on the uptake of genetic testing and impact on patient-reported psychological outcomes in families with pancreatic Cancer: the Genetic Education, Risk Assessment, and testing (GENERATE) study. Gastroenterol Feb 04. https://doi.org/10.1053/j.gastro.2024.01.042

34.

Trottier M, Lunn J, Butler R et al (2015) Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. Clin Genet 88(2):182–186. https://doi.org/10.1111/cge.12468CrossRefPubMed

35.

Beard VK, Bedard AC, Nuk J et al (2020) Genetic testing in families with hereditary colorectal cancer in British Columbia and Yukon: a retrospective cross-sectional analysis. CMAJ Open 8(4):E637–E642. https://doi.org/10.9778/cmajo.20190167CrossRefPubMedPubMedCentral

36.

Ponz de Leon M, Benatti P, Di Gregorio C et al (2004) Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. Br J Cancer 90(4):882–887. https://doi.org/10.1038/sj.bjc.6601529CrossRefPubMedPubMedCentral

37.

Blandy C, Chabal F, Stoppa-Lyonnet D, Julian-Reynier C (2003) Testing participation in BRCA1/2-positive families: initiator role of index cases. Genet Test 7(3):225–233. https://doi.org/10.1089/109065703322537241CrossRefPubMed

38.

Bednar EM, Sun CC, McCurdy S, Vernon SW (2020) Assessing relatives’ readiness for hereditary cancer cascade genetic testing. Genet Med 22(4):719–726. https://doi.org/10.1038/s41436-019-0735-3CrossRefPubMed

39.

Ponz de Leon M, Benatti P, Di Gregorio C et al (2004) Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. Br J Cancer Feb 23(4):882–887. https://doi.org/10.1038/sj.bjc.6601529CrossRef

40.

Ramsey ML, Tomlinson J, Pearlman R et al (2023) Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Fam Cancer Jan 22(1):91–97. https://doi.org/10.1007/s10689-022-00300-5CrossRef

41.

Cacioppo CN, Egleston BL, Fetzer D et al (2021) Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors. Cancer Med 07(13):4532–4541. https://doi.org/10.1002/cam4.3968CrossRef

42.

Shannon KM, Emmet MM, Rodgers LH, Wooters M, Seidel ML (2021) Transition to telephone genetic counseling services during the COVID-19 pandemic. J Genet Couns 30(4):984–988. https://doi.org/10.1002/jgc4.1365CrossRefPubMed

43.

Bradbury A, Patrick-Miller L, Harris D et al (2016) Utilizing Remote Real-Time videoconferencing to Expand Access to Cancer Genetic Services in Community practices: a Multicenter Feasibility Study. J Med Internet Res 18(2):e23. https://doi.org/10.2196/jmir.4564CrossRefPubMedPubMedCentral

44.

Kinney AY, Steffen LE, Brumbach BH et al (2016) Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 genetic counseling compared with In-Person counseling: 1-Year Follow-Up. J Clin Oncol 34(24):2914–2924. https://doi.org/10.1200/JCO.2015.65.9557CrossRefPubMedPubMedCentral

45.

Buchanan AH, Datta SK, Skinner CS et al (2015) Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: cost, patient satisfaction and attendance. J Genet Couns Dec 24(6):961–970. https://doi.org/10.1007/s10897-015-9836-6CrossRef

46.

Cremin C, Lee MK, Hong Q et al (2020) Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Med 06(11):4004–4013. https://doi.org/10.1002/cam4.2973CrossRef

47.

Brown EG, Watts I, Beales ER et al (2021) Videoconferencing to deliver genetics services: a systematic review of telegenetics in light of the COVID-19 pandemic. Genet Med Aug 23(8):1438–1449. https://doi.org/10.1038/s41436-021-01149-2CrossRef

48.

Swisher EM, Rayes N, Bowen D et al (2023) Remotely delivered Cancer Genetic Testing in the making genetic testing accessible (MAGENTA) trial: a Randomized Clinical Trial. JAMA Oncol Sep 14. https://doi.org/10.1001/jamaoncol.2023.3748

49.

National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, and Medicine; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research. Improving representation in clinical trials and research: building research equity for women and underrepresented groups. Bibbins-Domingo K, Helman A, editors. Washington (DC): National Academies Press (US); 2022 May 17. PMID: 36137057

50.

Herremans KM, Riner AN, Winn RA, Trevino JG (2021) Diversity and inclusion in pancreatic Cancer clinical trials. Gastroenterol Dec 161(6):1741–1746e3. https://doi.org/10.1053/j.gastro.2021.06.079CrossRef

51.

Tavakkoli A, Singal AG, Waljee AK et al (2020) Racial disparities and trends in Pancreatic Cancer incidence and mortality in the United States. Clin Gastroenterol Hepatol 01(1):171–178e10. https://doi.org/10.1016/j.cgh.2019.05.059CrossRef

52.

Schwartz AL, Alsan M, Morris AA, Halpern SD (2023) Why diverse clinical trial participation matters. N Engl J Med Apr 06(14):1252–1254. https://doi.org/10.1056/NEJMp2215609CrossRef

53.

Frey MK, Kahn RM, Chapman-Davis E et al (2020) Prospective feasibility trial of a novel strategy of facilitated cascade genetic testing using telephone counseling. J Clin Oncol 38(13):1389–1397. https://doi.org/10.1200/JCO.19.02005CrossRefPubMedPubMedCentral

54.

Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW (2019) Cascade Genetic Testing of relatives for Hereditary Cancer Risk: results of an Online Initiative. J Natl Cancer Inst 111(1):95–98. https://doi.org/10.1093/jnci/djy147CrossRefPubMed

55.

Gerido LH, Griggs JJ, Resnicow K et al (2023) The Michigan Genetic Hereditary Testing (MiGHT) study’s innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial. Trials Feb 10(1):105. https://doi.org/10.1186/s13063-023-07125-2CrossRef

Title: Expanding access to genetic testing for pancreatic cancer
Authors: Nicolette Juliana Rodriguez
Sapna Syngal
Publication date: 11-05-2024
Publisher: Springer Netherlands
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: Familial Cancer
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-024-00389-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer